| Code | CSB-RA015007MB20HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Rituximab-Pvvr, targeting MS4A1 (CD20), a transmembrane phosphoprotein exclusively expressed on the surface of B lymphocytes from pre-B to mature B cell stages. MS4A1 plays a crucial role in B cell activation, proliferation, and differentiation through regulation of calcium influx and cell cycle progression. This target is critically important in B cell-mediated autoimmune disorders and B cell malignancies, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, where aberrant B cell activity contributes to disease pathogenesis.
Rituximab-Pvvr is an FDA-approved therapeutic antibody that binds specifically to the CD20 antigen, mediating B cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis. This biosimilar antibody provides researchers with a valuable tool for investigating B cell biology, exploring mechanisms of B cell-mediated diseases, studying immune regulation, and developing novel therapeutic strategies targeting the CD20 pathway in oncology and autoimmune research contexts.
There are currently no reviews for this product.